Kosalaram Goteti

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis

Christopher Banfield, Matthew Scaramozza, Weidong Zhang et al. · The Journal of Clinical Pharmacology · 2017 · 94 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II with Reduced p<i>K</i>_a: Antibacterial Agents with an Improved Safety Profile

Folkert Reck, Richard A. Alm, Patrick Brassil et al. · Journal of Medicinal Chemistry · 2012 · 92 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 86 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8

Andreas Port, Jamie Shaw, Lena Klopp‐Schulze et al. · Pharmacology Research & Perspectives · 2021 · 54 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10

Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy

Jeremy D. Gale, Steven A. Gilbert, Samuel S. Blumenthal et al. · Kidney International Reports · 2018 · 51 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16